Complicated Skin And Skin Structure Staphylococcus Aureus Infection — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for complicated skin and skin structure staphylococcus aureus infection. 17 active patents protecting 3 drugs from 3+ originators. First major cliff: 2027. Daily refresh.

3
Approved drugs
17
Active US patents
46/100
Avg vulnerability
—
Annual revenue covered

Originators in Complicated Skin And Skin Structure Staphylococcus Aureus Infection

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Baxter 11 patents Fresenius Kabi 4 patents Cumberland 2 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating complicated skin and skin structure staphylococcus aureus infection. Each bar = one year. Y-axis scaled to peak year (5 patents).

2
27
2
28
1
29
2
30
5
33
4
38
1
41

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Cubicin
Daptomycin
 Baxter 11 63 — 2028-09-04
Tygacil
TIGECYCLINE
 Fresenius Kabi 4 49 — 2028-10-24
Vibativ
TELAVANCIN HYDROCHLORIDE
 Cumberland 2 27 — 2027-01-01

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
8003673 Cubicin method of use 80 2028-09-04
12053502 Cubicin method of use 75 2038-08-28
12053502 Cubicin method of use 75 2038-08-28
11173189 Cubicin method of use 70 2041-03-11
10357535 Cubicin method of use 62 2033-09-11
10357535 Cubicin method of use 62 2033-09-11
9655946 Cubicin method of use 62 2033-09-11
9655946 Cubicin method of use 62 2033-09-11
7879828 Tygacil formulation 60 2029-02-05
8975242 Tygacil formulation 55 2028-10-24

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
7531623 Vibativ composition of matter 27 2027-01-01
7531623 Vibativ composition of matter 27 2027-01-01
9855335 Tygacil formulation 42 2033-04-07
9138456 Cubicin formulation 48 2030-11-23
11759497 Cubicin formulation 50 2038-08-28
11759497 Cubicin formulation 50 2038-08-28
8372995 Tygacil formulation 53 2030-10-08
8975242 Tygacil formulation 55 2028-10-24
7879828 Tygacil formulation 60 2029-02-05
10357535 Cubicin method of use 62 2033-09-11

Related